CYP3A4 and AIDS: Rifamycin derivatives such as RFP usually induce CYP3A4 enzymes, remarkably reducing the bioavailability of the drug itself as well as other CYP-intermediated drugs, including protease inhibitors, which are indispensable in the treatment of HIV/AIDS [37].